Pre-Eclampsia Pipeline Insights Report 2024 Featuring Gmax Biopharm, Vicore Pharma, and Comanche Biopharma
27 févr. 2024 11h26 HE
|
Research and Markets
Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Pre-Eclampsia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report report provides comprehensive...
Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia
17 janv. 2024 06h00 HE
|
Comanche Biopharma
Comanche Biopharma closes oversubscribed $75 Million Series B financing to advance first treatment targeting a root cause of preeclampsia.
Global Polycystic Ovary Syndrome Treatment Market Report 2023: Sector is Expected to Reach $1.5 Billion by 2030 at a CAGR of 4.9%
01 juin 2023 11h23 HE
|
Research and Markets
Dublin, June 01, 2023 (GLOBE NEWSWIRE) -- The "Polycystic Ovary Syndrome Treatment Market, By Drug Class, By Distribution Channel, By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 -...
Pre-Eclampsia - Pipeline Insight, 2023: Featuring Analysis of Key Projects from Kyowa Kirin, Gmax Biopharm and Vicore Pharma
24 mai 2023 04h28 HE
|
Research and Markets
Dublin, May 24, 2023 (GLOBE NEWSWIRE) -- The "Pre-Eclampsia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights...
With 2.2% CAGR, Preeclampsia Diagnostics Market Size worth USD 1.24 Billion by 2029
16 août 2022 08h24 HE
|
Fortune Business Insights
Pune, India, Aug. 16, 2022 (GLOBE NEWSWIRE) -- The global preeclampsia diagnostics market size was valued at USD 1.03 billion in 2021 and reached USD 1.07 billion in 2022. The market is expected to...
Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test
14 sept. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has...
Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test
29 juil. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today successful completion of the validation study for its Preecludia™...
Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline
02 juin 2021 07h00 HE
|
Progenity, Inc.
Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to...
Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations
25 mai 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business...
Progenity Joins Global Call to Raise Awareness of Preeclampsia in Pregnancy on World Preeclampsia Day – May 22nd
21 mai 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, May 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...